Compare ATLO & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | RNA |
|---|---|---|
| Founded | 1903 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.2M | 199.7M |
| IPO Year | 2001 | 2025 |
| Metric | ATLO | RNA |
|---|---|---|
| Price | $28.51 | $12.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $69.26 |
| AVG Volume (30 Days) | 62.5K | ★ 322.1K |
| Earning Date | 04-24-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | N/A | $18.11 |
| P/E Ratio | $74.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.94 | $11.95 |
| 52 Week High | $29.71 | $73.06 |
| Indicator | ATLO | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 32.51 |
| Support Level | $26.00 | $12.85 |
| Resistance Level | $29.71 | $14.80 |
| Average True Range (ATR) | 0.65 | 0.62 |
| MACD | -0.05 | 0.62 |
| Stochastic Oscillator | 56.38 | 19.83 |
Ames National Corporation is a bank holding company based in the United States. Through its subsidiaries, it provides a range of banking and other financial products and services to customers in Iowa, mainly in Boone, Clarke, Hancock, Marshall, Polk, Story, Taylor, and Union in central, north-central, and south-central Iowa. The Group offers several financial products and services, including checking and savings accounts, time deposits, commercial, construction, and agricultural loans, personal loans, lines of credit, cash management services, merchant credit card processing, safe deposit boxes, and ATM services, among others. It caters to the banking needs of a diverse range of customers, including individuals, businesses, professionals, and enterprises.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.